Richard Markus, Dantari CEO

Sol­id tu­mor biotech’s poly­mer nanopar­ti­cle-drug con­ju­gate clears ear­ly-stage hur­dle, spark­ing PhII plans

Dan­tari’s drug con­ju­gate as­set has pro­duced pos­i­tive da­ta as both a monother­a­py and in com­bi­na­tion with a PARP in­hibitor in an ear­ly-stage breast can­cer tri­al, paving the way for a Phase II test.

The biotech’s Phase I dose es­ca­la­tion tri­al stud­ied DAN-222 as a sin­gle agent and in com­bi­na­tion with GSK’s Ze­ju­la in 30 metasta­t­ic HER2-neg­a­tive breast can­cer pa­tients with a me­di­an of six pri­or lines of ther­a­py. Re­sults from the tri­al come one year af­ter Dan­tari raised $47 mil­lion in a Se­ries A round.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.